Veterinary Medicines

Bravoxin 10 suspension for injection for cattle and sheep

Not authorised
  • Clostridium novyi, type D, toxoid
  • Clostridium sordellii, toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium novyi, toxoid
  • Clostridium chauvoei, Inactivated
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium perfringens, type B, beta toxoid
  • Clostridium perfringens, type A, alpha toxoid
Download as PDF

Product identification

Medicine name:
Bravoxin 10 suspension for injection for cattle and sheep
BRAVOXIN 10
Active substance:
  • Clostridium novyi, type D, toxoid
  • Clostridium sordellii, toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium novyi, toxoid
  • Clostridium chauvoei, Inactivated
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium perfringens, type B, beta toxoid
  • Clostridium perfringens, type A, alpha toxoid
Target species:
  • Cattle
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium novyi, type D, toxoid
    17.40
    unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium sordellii, toxoid
    4.40
    international unit(s)
    /
    1.00
    millilitre(s)
  • Tetanus toxoid adsorbed
    4.90
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium septicum, toxoid
    4.60
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium novyi, toxoid
    3.80
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium chauvoei, Inactivated
    90.00
    percentage protection
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type D, epsilon toxoid
    5.30
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type C, beta toxoid
    18.20
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type B, beta toxoid
    18.20
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type A, alpha toxoid
    0.50
    enzyme-linked immunosorbent assay unit
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
    • Sheep
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AB01
  • QI04AB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • France
Package description:
  • (ID1): 1 Box with 1 Bottle (Low Density PolyEthylene) with 20 millilitre(s) (20 millilitre(s))
  • (ID2): 1 Box with 1 Bottle (Low Density PolyEthylene) with 50 millilitre(s) (50 millilitre(s))
  • (ID3): 1 Box with 1 Bottle (Low Density PolyEthylene) with 100 millilitre(s) (100 millilitre(s))

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet
Marketing authorisation date:
Manufacturing sites for batch release:
  • MSD Animal Health UK Limited
  • Intervet International B.V.
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/6627427 6/2008
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0279/001

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 4/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."